Imugene CEO Discusses Enrolment for Bile Tract Cancer Expansion Study
Imugene CEO Leslie Chong discusses enrolment for a pivotal expansion study targeting bile tract cancer patients, following the successful completion of the VAXINIA monotherapy dose escalation study.
The news highlights the ongoing efforts of Imugene Ltd to advance innovative oncological treatments, with promising results in gastrointestinal cancers. The expansion study could provide hope for cholangiocarcinoma patients, and the presentation at the upcoming conference demonstrates the company's commitment to gathering support for its cutting-edge therapies.